IRIS
MAROSTICA, ELEONORA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 501
EU - Europa 327
AS - Asia 236
AF - Africa 1
Totale 1.065
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 491
CN - Cina 235
IE - Irlanda 137
UA - Ucraina 61
FI - Finlandia 43
DE - Germania 27
SE - Svezia 20
GB - Regno Unito 15
IT - Italia 13
CA - Canada 6
BE - Belgio 5
MX - Messico 4
PT - Portogallo 3
FR - Francia 1
GR - Grecia 1
HK - Hong Kong 1
MU - Mauritius 1
NL - Olanda 1
Totale 1.065
Salva come PNG Salva come JPEG
Città #
Dublin 137
Chandler 120
Jacksonville 86
Nanjing 62
Beijing 42
Ann Arbor 29
Ashburn 28
Wilmington 28
Nanchang 27
Jiaxing 20
Princeton 18
Dearborn 17
Hebei 17
Lawrence 16
Shenyang 16
Tianjin 16
Medford 13
Boardman 10
Houston 10
Shanghai 10
Helsinki 8
Milan 8
Brussels 5
Changsha 5
Hangzhou 5
Renton 5
Seattle 5
Toronto 5
Woodbridge 5
Morelia 4
Bobadela 3
Falls Church 3
Jinan 3
Kunming 3
Lanzhou 3
Los Angeles 3
Ningbo 3
Norwalk 2
Pavia 2
Washington 2
Dolo 1
Groningen 1
Hefei 1
Newton 1
Piscataway 1
Redwood City 1
San Francisco 1
Surrey 1
Tappahannock 1
Vicenza 1
Xian 1
Totale 815
Salva come PNG Salva come JPEG
Nome #
First-order longitudinal population model of FEV1 data: single-trial modeling and meta-analysis 86
Continuous-time Markov modelling of flexible-dose depression trials 78
Population Pharmacokinetic Model of Ibrutinib, a BTK Inhibitor for the Treatment of B-cell malignancies 70
Integration of response, tolerability and dropout in flexible-dose trials: a case study in depression 68
A state-space approach to disease and dropout modelling in Phase II clinical trials 66
Second order Markov modelling of HAMD responses in depression trials 66
Population state-space modelling of patient responses in antidepressant studies 65
A PCA approach to population analysis: with application to a Phase II depression trial 62
Second-order indirect response modelling of complex biomarker dynamics 61
PCA-based modelling in antidepressant trials: a pre-mechanistic approach 57
Disease and dropout modelling in depression trials: a state-space approach 55
Joint Modeling of Efficacy, Dropout, and Tolerability in Flexible-Dose Trials: A Case Study in Depression 55
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies 54
The GHRH+arginine stimulated pituitary GH secretion in children and adults with Prader-Willi syndrome shows age- and BMI-dependent and genotype-related differences 50
Population model of longitudinal FEV1 data in asthmatics: meta-analysis and predictability of placebo response 48
Deconvolution-based assessment of pituitary GH secretion stimulated with GHRH+arginine in Prader-Willi adults and obese controls 47
A new, second-order indirect model of depression time course 42
Population modelling of patient responses in antidepressant studies: A stochastic approach 40
Totale 1.070
Salva come PNG Salva come JPEG
Categoria #
all - tutte 3.486
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.486
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201914 0 0 0 0 0 0 0 0 0 0 7 7
2019/2020281 73 89 2 13 2 13 0 28 19 33 8 1
2020/2021125 17 12 5 14 0 15 2 17 3 20 16 4
2021/202279 3 1 5 3 3 3 2 5 8 1 10 35
2022/2023332 25 34 5 26 26 32 0 14 157 5 7 1
2023/2024104 17 20 2 15 5 18 4 12 0 7 4 0
Totale 1.070